Biotechnological Potential of Eugenol and Thymol Derivatives Against Staphylococcus aureus from Bovine Mastitis

Nunes, Daiana O S; Vinturelle, Rafaelle; Martins, Francislene Juliana; Santos, Thiago F Dos; Valverde, Alessandra L.; Ribeiro, Carlos Magno Rocha; Castro, Helena C.; Folly, Evelize

doi:10.1007/s00284-021-02344-9

Cited by 6 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Positive drug‐likeness (0.1–10) indicates that a compound has fragments that usually exist in commercially used drugs. Both Au(III) compounds present negative drug‐likeness, suggesting that they differ from drugs on the market 35 . Log S (aqueous solubility) is an effective parameter that indicates the distribution and absorption characteristics of a given compound.…”

Section: Resultsmentioning

confidence: 99%

“…Both Au(III) compounds present negative drug-likeness, suggesting that they differ from drugs on the market. 35 Log S (aqueous solubility) is an effective parameter that indicates the distribution and absorption characteristics of a given compound. The acceptable range of Log S for a drug candidate is between À6.5 and 0.5.…”

Section: In Silico Descriptors Profilementioning

confidence: 99%

See 1 more Smart Citation

Au(III) complexes of symmetrical tetradentate Schiff base ligands: Synthesis, characterization, anticancer/antioxidant potency, in silico prediction, and catalase binding properties

Keikha

Shahraki

Mansouri‐Torshizi

et al. 2023

Applied Organom Chemis

View full text Add to dashboard Cite

Two new gold(III) complexes, [AuL 1 ]Cl 3 , A, and [AuL 2 ]Cl 3 , B, were synthesized and characterized. DFT calculations showed square planar geometry for both complexes. Antioxidant results showed that the ability of compounds to inhibit DPPH• is as follows: A > B > L 2 > L 1 . The anticancer assay showed that both complexes have the ability to inhibit the growth of HCT116 colon cancer cell lines, but B shows a relatively better effect than cisplatin. The interaction effects of A and B on the activity and structure of the bovine liver catalase (BLC) were investigated by spectroscopic techniques and molecular docking. Both complexes were able to change the performance and structure of BLC; B has a greater effect on BLC activity, so at concentration of 2 μM, A and B inhibit initial BLC activity by 92.2% and 55.6%, respectively. The interaction mechanism of A and B with BLC was also different; A interacted mostly with van der Waals interactions and hydrogen bonds, but the most important forces for B was hydrophobic interactions. According to docking results, both complexes prefer the domain III of BLC, but B has higher affinity toward BLC than A, which supports the results of spectroscopic and FMO analysis.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: In Silico Descriptors Profilementioning

confidence: 99%

Au(III) complexes of symmetrical tetradentate Schiff base ligands: Synthesis, characterization, anticancer/antioxidant potency, in silico prediction, and catalase binding properties

Keikha

Shahraki

Mansouri‐Torshizi

et al. 2023

Applied Organom Chemis

View full text Add to dashboard Cite

show abstract

“…Eugenol is known to have antioxidative, analgesic, antimutagenic, antiplatelet, anti-swelling, and anti-inflammatory effects. It also possesses antimicrobial properties against a variety of human pathogens, including a variety of Gram-positive and Gram-negative bacteria, fungi, and parasites [ 18 , 19 ].…”

Section: Introductionmentioning

confidence: 99%

A Comprehensive in vitro and in silico Assessment on Inhibition of CYP51B and Ergosterol Biosynthesis by Eugenol in Rhizopus oryzae

et al. 2022

View full text Add to dashboard Cite

Mucormycosis, also known as Zygomycosis, is a disease caused by invasive fungi, predominantly Rhizopus species belonging to the Order of Mucorales . Seeing from the chemistry perspective, heterocyclic compounds with an "azole" moiety are widely employed as antifungal agent for minimising the effect of mucormycosis as a prescribed treatment. These azoles serve as non-competitive inhibitors of fungal CYP51B by predominantly binding to its heme moiety, rendering its inhibition. However, long-term usage and abuse of azoles as antifungal medicines has resulted in drug resistance among certain fungal pathogens. Hence, there is an unmet need to find alternative therapeutic compounds. In present study, we used various in vitro tests to investigate the antifungal activity of eugenol against R. oryzae/R. arrhizus , including ergosterol quantification to test inhibition of ergosterol production mediated antifungal action. The minimum inhibitory concentration (MIC) value obtained for eugenol was 512 μg/ml with reduced ergosterol concentration of 77.11 ± 3.25% at MIC/2 concentration. Further, the molecular interactions of eugenol with fungal CYP51B were meticulously studied making use of proteomics in silico study including molecular docking and molecular dynamics simulations that showed eugenol to be strongly interacting with heme in an identical fashion to that shown by azole drugs (in this case, clotrimazole was evaluated). This is the first of a kind study showing the simulation study of eugenol with CYP51B of fungi. This inhibition results in ergosterol synthesis and is also studied and compared with keeping clotrimazole as a reference. Graphical Abstract

show abstract

Eugenol

Ataei¹,

Maghsoudi²,

Hassani³

2024

Encyclopedia of Toxicology

View full text Add to dashboard Cite

Biotechnological Potential of Eugenol and Thymol Derivatives Against Staphylococcus aureus from Bovine Mastitis

Cited by 6 publications

References 30 publications

Au(III) complexes of symmetrical tetradentate Schiff base ligands: Synthesis, characterization, anticancer/antioxidant potency, in silico prediction, and catalase binding properties

Au(III) complexes of symmetrical tetradentate Schiff base ligands: Synthesis, characterization, anticancer/antioxidant potency, in silico prediction, and catalase binding properties

A Comprehensive in vitro and in silico Assessment on Inhibition of CYP51B and Ergosterol Biosynthesis by Eugenol in Rhizopus oryzae

Eugenol

Contact Info

Product

Resources

About